Sanofi’s MenQuadfi Receives EU Approval for Infants From Six Weeks of Age
PARIS, Aug. 4, 2026 Sanofi announced that the European Commission (EC) has approved an expanded indication for MenQuadfi® (Meningococcal...
pirtobrutinib
Advertisement
Nurix Therapeutics Enrolls First Patient in Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg
BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...
Lilly Jaypirca CHMP Backs EU Approval for CLL Treatment
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Advertisement
